South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

MSD’s Keytruda has become the first checkpoint inhibitor ... the use of the drug into patients with earlier-stage cancer - a key strategy for MSD and other cancer immunotherapy companies ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending ...

Mark’s decades of experience using research with critical audiences to develop strategy and campaigns for political, corporate, and government entities will be a key differentiator for our ...

this item is currently being modified/updated by the task: derive Rotating panelists discuss the big news of the day and react to the top stories.